Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amylin CEO: Firm Can Do Better With Byetta

This article was originally published in The Pink Sheet Daily

Executive Summary

Diabetes drug so far has failed to catch on with primary-care docs.

You may also be interested in...



Amylin, Lilly Partnership Tested By Lilly GLP-1 Project

Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.

Amylin, Lilly Partnership Tested By Lilly GLP-1 Project

Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.

Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says

FDA's review of a new monotherapy indication for Amylin's type 2 diabetes agent Byetta (exenatide) may provide the opportunity for updating the labeling to reflect a stronger warning on pancreatitis

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel